Physician profile
Leah A Lima
NPI 1003571373
$2,733.22
in general payments reported to CMS, 2019-2025
20 companies · $820 in 2025
The $820 reported for 2025 was more than what 77% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $182 · 2022: $880 · 2023: $799 · 2024: $51.20 · 2025: $820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,670.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $589.50 | 2022-2025 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $355.57 | 2025 | Auvelity |
| Abbvie INC. | $288.24 | 2022-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $284.79 | 2022-2023 | |
| Alkermes, INC. | $260.60 | 2022-2025 | Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $211.81 | 2021-2023 | Spravato |
| Braeburn INC. | $189.10 | 2024-2025 | Brixadi |
| Indivior INC. | $146.52 | 2025 | Sublocade |
| Lundbeck LLC | $73.01 | 2022-2023 | Rexulti |
| Jazz Pharmaceuticals INC. | $65.79 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $56.31 | 2022 | |
| Corium, LLC | $32.95 | 2023 | Azstarys |
| Vanda Pharmaceuticals INC. | $32.31 | 2022 | |
| Idorsia Pharmaceuticals US INC | $26.64 | 2022-2023 | Quviviq |
| Owp Pharmaceuticals, INC. | $23.66 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $21.81 | 2022 | |
| Tempus Ai, INC | $20.86 | 2024 | |
| Almatica Pharma LLC | $19.61 | 2021 | |
| Tris Pharma INC | $17.93 | 2023 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $16.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leah Lima listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.